Loading…
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | $-108M | $-109M | $-94M | -44.1% | 17.3% | - |
| 2024 | $8M | $-88M | $-89M | $-82M | -124.8% | -46.1% | - |
| 2023 | $15M | $-105M | $-112M | $-80M | -148.9% | 517.5% | - |
| 2022 | $3M | $-161M | $-166M | $-113M | -17493.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 2.50 | 15.45 | 8.33 | 9.77 |
| Operating Expense | 128.53 | 86.83 | 94.95 | 120.27 |
| Operating Income | -126.03 | -71.37 | -86.62 | -110.50 |
| EBITDA | -161.04 | -105.20 | -87.95 | -107.79 |
| EBIT | -162.22 | -106.57 | -89.20 | -108.93 |
| Pretax Income | -166.01 | -111.57 | -89.30 | -109 |
| Net Income | -166.01 | -111.57 | -89.30 | -109 |
| Net Income Common Stockholders | -166.01 | -111.57 | -89.30 | -109 |
| Total Expenses | 128.53 | 86.83 | 94.95 | 120.27 |
| Interest Expense | 3.80 | 5 | 0.10 | 0.06 |
| Interest Income | 0.25 | 3.57 | 6.94 | 9.22 |
| Research And Development | 91.17 | 56.78 | 66 | 86.40 |
| Selling General And Administration | 37.36 | 30.05 | 28.95 | 33.87 |
| Normalized EBITDA | -124.62 | -68.02 | -83.13 | -106.59 |
| Normalized Income | -129.59 | -74.39 | -84.48 | -107.80 |
| Basic EPS | -3.78 | -0.96 | -0.36 | 0 |
| Diluted EPS | -3.78 | -0.96 | -0.36 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -36.42 | -37.18 | -4.82 | -1.20 |
| Total Unusual Items Excluding Goodwill | -36.42 | -37.18 | -4.82 | -1.20 |
| Net Income From Continuing Operation Net Minority Interest | -166.01 | -111.57 | -89.30 | -109 |
| Reconciled Depreciation | 1.17 | 1.37 | 1.25 | 1.15 |
| Net Interest Income | -3.55 | -1.43 | 6.84 | 9.16 |
| Net Income From Continuing And Discontinued Operation | -166.01 | -111.57 | -89.30 | -109 |
| Total Operating Income As Reported | -162.45 | -72.44 | -91.46 | -110.50 |
| Diluted Average Shares | 43.95 | 116.12 | 250.13 | 0 |
| Basic Average Shares | 43.95 | 116.12 | 250.13 | 0 |
| Diluted NI Availto Com Stockholders | -166.01 | -111.57 | -89.30 | -109 |
| Net Income Including Noncontrolling Interests | -166.01 | -111.57 | -89.30 | -109 |
| Net Income Continuous Operations | -166.01 | -111.57 | -89.30 | -109 |
| Other Income Expense | -36.44 | -38.77 | -9.52 | -7.66 |
| Other Non Operating Income Expenses | -0.02 | -1.58 | -4.69 | -6.46 |
| Special Income Charges | -36.42 | -2.46 | -4.84 | 0 |
| Other Special Charges | 0 | 1.40 | 0 | 0 |
| Impairment Of Capital Assets | 36.42 | 1.06 | 4.84 | 0 |
| Gain On Sale Of Security | 0 | -34.72 | 0.02 | -1.20 |
| Net Non Operating Interest Income Expense | -3.55 | -1.43 | 6.84 | 9.16 |
| Interest Expense Non Operating | 3.80 | 5 | 0.10 | 0.06 |
| Interest Income Non Operating | 0.25 | 3.57 | 6.94 | 9.22 |
| General And Administrative Expense | 37.36 | 30.05 | 28.95 | 33.87 |
| Other Gand A | 37.36 | 30.05 | 28.95 | 33.87 |
| Operating Revenue | 2.50 | 15.45 | 8.33 | 9.77 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc.this co. | TSHA | $1.8B | - | 7.24 | -44.1% | -14.19 |
| GeneDx Holdings Corp. | WGS | $1.8B | - | 5.97 | -6.8% | 141.02 |
| Inhibrx Biosciences, Inc. | INBX | $1.8B | - | 227.77 | -1752.2% | -13.63 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.8B | - | 27.92 | -441.6% | -6.40 |
| Surgery Partners, Inc. | SGRY | $1.8B |
| - |
| 1.04 |
| -2.2% |
| 11.28 |
| AnaptysBio, Inc. | ANAB | $1.8B | - | 46.94 | -35.6% | 36.55 |
| Sonida Senior Living, Inc. | SNDA | $1.8B | - | -37500.00 | -125.8% | 57.41 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.8B | 11.23 | 2.05 | 18.2% | 4.68 |
| Palvella Therapeutics, Inc. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Peer Median | - | 11.23 | 16.94 | -80.7% | 11.28 | |